RVNC: Revance Therapeutics, Inc. Stock

by  •  • Comments Off on RVNC: Revance Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 392.89
Enterprise Value ($M) 684.66
Book Value ($M) -151.60
Book Value / Share -1.45
Price / Book -2.59
NCAV ($M) -291.19
NCAV / Share -2.79
Price / NCAV -1.35

Profitability (mra)
Return on Invested Capital (ROIC) -0.99
Return on Assets (ROA) -0.59
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 3.29
Current Ratio 3.80

Balance Sheet (mrq) ($M)
Current Assets 338.87
Assets 478.45
Liabilities 630.06
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 234.04
Operating Income -220.72
Net Income -323.99
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -216.57
Cash from Investing 109.74
Cash from Financing 136.57

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-09 13G/A Jpmorgan Chase & Co 2.60 -41.77
02-14 13G/A Antara Capital LP 0.00 -100.00
02-14 13G/A Palo Alto Investors LP 5.96 -0.88
02-13 13G/A Vanguard Group Inc 5.77 12.75
02-13 13G/A Polar Capital Holdings Plc 3.60 -34.64
02-09 13G/A GIC Private Ltd 6.63 6.06
02-09 13G/A Capital World Investors 13.60 25.94
02-06 13G Franklin Resources Inc 6.80 247.88
01-25 13G/A BlackRock Inc. 8.50 5.38
10-24 13D/A Teoxane SA 7.40 47.35

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PUR
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 244,348 1,401,069 17.44
2024-05-02 249,291 1,107,840 22.50
2024-05-01 436,199 1,960,600 22.25
2024-04-30 352,263 881,394 39.97
2024-04-29 794,802 845,056 94.05

(click for more detail)

Similar Companies
RNA – Avidity Biosciences, Inc. RNAC – Cartesian Therapeutics, Inc.
RPHM – Reneo Pharmaceuticals, Inc. RWOD – Redwoods Acquisition Corp.
RYTM – Rhythm Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io